Advanced dual-barrel nanopipettes enable rapid, multiplex bacterial detection, suggesting a breakthrough in diagnostics.
Bacterial detection remains a global public health challenge, demanding rapid and precise detection strategies. Conventional nucleic acid or antigen-based assays face challenges of high costs and contamination risks. Conversely, bacterial enzymes represent attractive targets due to their strain-specific expression and inherent catalytic amplification capacity. Herein, we developed an enzyme-responsive dual-barrel nanopipette with heterogeneously modified nanointerfaces for sensitive, label-free, multiplex bacterial detection. Two independently functionalized channels integrate enzyme-triggered surface charge switching with nanofluidic ionic current rectification (ICR) characterization. Exposure to β-galactosidase (β-Gal) or β-glucuronidase (β-Glu) selectively alters channel surface charges, thereby modulating interchannel charge asymmetry. Leveraging bacterial enzymatic fingerprints, the nanopipette generates species-specific ICR signatures for label-free quantification within 30 min, achieving detection limits of 12 CFU/mL for E. coli and 126 CFU/mL for K. pneumoniae. The practical applicability was validated across diverse complex matrices: recovery rates of 97.49-106.94% in milk and drinking water, and 101.37-113.91% in serum (5000-50,000 CFU/mL), demonstrating its potential for diagnosing moderate bacterial infections. The innovation lies in the label-free operation, rapid response, and multiplexing capability of this sensor, which addresses critical limitations in current bacterial monitoring systems and offers a cost-effective on-site pathogen screening platform for applications spanning food safety and clinical diagnostics.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: